Cardio Diagnostics Holdings Inc
Research Cardio Diagnostics Holdings Inc (CDIO) on Bullrun: market cap USD 5.65M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCDIO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 5.65M
- Financial periodQ1 2026
- RevenueUSD 16.57K
- Net income-USD 1.79M
- Free cash flow-USD 1.63M
Valuation Snapshot
latest market cap is USD 5.65M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 14.83K | -USD 6.50M | -USD 5.91M | n/a | -3.71 | USD 0 | USD 695.62K | USD 6.97M |
| FY2024 | USD 34.89K | -USD 8.38M | -USD 5.21M | n/a | -9.35 | USD 0 | USD 969.86K | USD 9.56M |
| FY2023 | USD 17.07K | -USD 8.38M | -USD 6.25M | n/a | -0.66 | USD 0 | USD 887.03K | USD 2.96M |
| FY2022 | USD 950 | -USD 4.66M | n/a | n/a | -1.51 | USD 0 | n/a | USD 4.30M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 5.65M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 4.95M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 42.13M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 51.09M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 10.09M | n/a | n/a | n/a |
About Cardio Diagnostics Holdings Inc
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cardio Diagnostics Holdings Inc's market cap?
Cardio Diagnostics Holdings Inc's market capitalization is USD 5.65M.
What does Cardio Diagnostics Holdings Inc do?
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management.